Scholarlink

<p>Acute chest pain is a life-threatening clinical emergency requiring rapid differentiation of acute myocardial infarction (AMI), acute aortic dissection (AAD), and pulmonary embolism (PE). Conventional diagnostics are limited by bulky equipment, delayed processing, and insufficient specificity. We developed a portable dual-readout lateral flow immunoassay (Multi-AuPd@Fe<sub><i>x</i></sub>O<sub><i>y</i></sub>-LFIA) for one-step identification of high-risk acute chest pain etiologies, enabling simultaneous determination of five key biomarkers: soluble suppression of tumorigenicity 2 (sST2), D-Dimer, cardiac troponin I (cTnI), myoglobin (MYO), and C-reactive protein (CRP). A 3D-printed smartphone cradle and APP enabled automated signal readout. The multi-AuPd@Fe<sub><i>x</i></sub>O<sub><i>y</i></sub>-LFIA exhibits low limits of detection (LODs) of 0.036 ng/mL (sST2), 0.008 µg/mL (D-Dimer), 0.017 ng/mL (cTnI), 0.732 ng/mL (MYO), and 3.327 µg/mL (CRP). Based on the analysis of the concentrations of the five biomarkers in 137 clinical plasma samples, least absolute shrinkage and selection operator (LASSO) machine learning establishes a four-category classification model, with areas under curves (AUCs) reaching 0.99–1.00 for distinguishing healthy donors, AMI, AAD, and PE. The established machine learning diagnostic algorithm is further integrated into the App, enabling Multi-AuPd@Fe<sub><i>x</i></sub>O<sub><i>y</i></sub>-LFIA to achieve quantitative detection and early differential diagnosis of acute chest pain.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multiplexed Lateral Flow Immunoassay with Catalytic Signal Amplification for Simultaneous Quantitative Detection of Five Cardiac Biomarkers in Acute Chest Pain Triage

  • 期刊论文

  • 发表日期：

    2026年7月4日

查看全文
  • Dan Song,
  • Haodong Wang,
  • Xudong Sun,
  • Fuchao Wu,
  • Qian Tong,
  • Zhen-Xin Wang

摘要

Acute chest pain is a life-threatening clinical emergency requiring rapid differentiation of acute myocardial infarction (AMI), acute aortic dissection (AAD), and pulmonary embolism (PE). Conventional diagnostics are limited by bulky equipment, delayed processing, and insufficient specificity. We developed a portable dual-readout lateral flow immunoassay (Multi-AuPd@FexOy-LFIA) for one-step identification of high-risk acute chest pain etiologies, enabling simultaneous determination of five key biomarkers: soluble suppression of tumorigenicity 2 (sST2), D-Dimer, cardiac troponin I (cTnI), myoglobin (MYO), and C-reactive protein (CRP). A 3D-printed smartphone cradle and APP enabled automated signal readout. The multi-AuPd@FexOy-LFIA exhibits low limits of detection (LODs) of 0.036 ng/mL (sST2), 0.008 µg/mL (D-Dimer), 0.017 ng/mL (cTnI), 0.732 ng/mL (MYO), and 3.327 µg/mL (CRP). Based on the analysis of the concentrations of the five biomarkers in 137 clinical plasma samples, least absolute shrinkage and selection operator (LASSO) machine learning establishes a four-category classification model, with areas under curves (AUCs) reaching 0.99–1.00 for distinguishing healthy donors, AMI, AAD, and PE. The established machine learning diagnostic algorithm is further integrated into the App, enabling Multi-AuPd@FexOy-LFIA to achieve quantitative detection and early differential diagnosis of acute chest pain.